ADC Therapeutics (ADCT) Amortization of Deferred Charges (2023 - 2026)
ADC Therapeutics has reported Amortization of Deferred Charges over the past 4 years, most recently at $225000.0 for Q1 2026.
- Quarterly results put Amortization of Deferred Charges at $225000.0 for Q1 2026, up 17.8% from a year ago — trailing twelve months through Mar 2026 was $1.9 million (up 214.24% YoY), and the annual figure for FY2025 was $1.8 million, up 101.77%.
- Amortization of Deferred Charges reached $225000.0 in Q1 2026 per ADCT's latest filing, down from $246000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $830000.0 in Q1 2023 and bottomed at -$557000.0 in Q4 2024.
- Median Amortization of Deferred Charges over the past 4 years was $516000.0 (2024), compared with a mean of $458692.3.
- The largest annual shift saw Amortization of Deferred Charges crashed 180.26% in 2024 before it soared 144.17% in 2025.
- Over 4 years, Amortization of Deferred Charges stood at $694000.0 in 2023, then plummeted by 180.26% to -$557000.0 in 2024, then soared by 144.17% to $246000.0 in 2025, then decreased by 8.54% to $225000.0 in 2026.
- Business Quant data shows Amortization of Deferred Charges for ADCT at $225000.0 in Q1 2026, $246000.0 in Q4 2025, and $733000.0 in Q3 2025.